H D I N S I G H T S
T M
T H A N K S L U N D B E C K F O R I T S
G E N E R O U S S U P P O R T
Copyright © Huntington Study Group 2014. All rights reserved.
SPONSOR STUDY
NAME/
IDENTIFIER
STUDY
AGENT
PHASE
PRINCIPAL
INVESTIGATOR,
CONTACT
DESIGN TRIAL
LENGTH
SITES STATUS
Teva
Pharmaceutical
Industries
PRIDE-HD Pridopidine
II
Teva US Medical
Information
800-896-5855
Randomized, double-blind, placebo-controlled
study of safety and efficacy of pridopidine 45
mg, 67.5 mg, 90 mg, and 112.5 mg BID versus
placebo for symptomatic treatment in patients
with HD
26 weeks U.S.
Currently
enrolling
Teva
Pharmaceutical
Industries
OPEN-HART
Pridopidine
II
Karl Kieburtz, MD,
MPH
Open-label, single group assignment study to
assess the long-term safety of 45 mg of
pridopidine in HD participants
2 years
22 sites -
U.S. and
Canada
Enrollment
complete, study
ongoing
Teva
Pharmaceutical
Industries
Legato-HD Laquinimod
II
Teva US Medical
Information
800-896-5855
Randomized, double-blind, placebo-controlled,
parallel-group study evaluating efficacy and
safety of Laquinimod (0.5, 1.0 and 1.5 mg/day)
in HD
12 months
46 sites -
worldwide
Not yet
recruiting
Clinical Trials, cont...
To update or add a clinical trial, please e-mail editor@hdinsights.org.
Sources: www.clinicaltrials.gov and apps.who.int/trialsearch/
H D I N S I G H T S
HD Insights, Vol. 9 11
